Donate For Public and Patients Store Search

S051 - Dilemmas and Challenges in Skin Cancer Therapies and Management

Monday, March 4; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Apply new results from research and the literature to their clinical practice setting to benefits their patients
  • Integrate new concepts into clinical practice related to skin cancer on a regular basis.


Therapeutic and management Issues related to skin cancer are dealt with on a daily basis by Dermatologists and lack of a comprehensive therapeutic and management issues can lead to increased morbidity and mortality. This course will be designed to related present key factors that impact on patient care and how to apply current therapies and management approaches. Spirited Questions and Answers with active audience participation will be encouraged. This symposium will work toward delivering practical therapeutic and management solutions to these issues that can be immediately incorporated into the attendee’s patient care setting. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at


  • Ceilley, Roger I., MD: Aclaris Therapeutics Inc. – A(H); Biofrontera AG – A(H); Ferndale Laboratories, Inc. – A(H); Pfizer Inc. – A(H); Sun Pharmaceutical Industries Ltd. – A(H);
  • Desai, Seemal R., MD: AbbVie – I(Grants/Research Funding); Almirall – C(Fees), SP(H); Cassiopea SpA – C(H); Dermavant Sciences – A(Fees); Dermira – C(H), I(Grants/Research Funding), SP(H); Dr. Reddy – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – A(Fees); Galderma Laboratories, LP – C(Fees); Menlo Therapeutics – C(H), I(Grants/Research Funding); Ortho Dermatologics – C(H), SP(H); Pfizer Inc. – SP(H); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Scientis – C(H), SP(H); SkinCeuticals LLC – C(H);
  • Farberg, Aaron, MD: Castle Biosciences – I(Grants/Research Funding); Celgene – A(H); Eclipse Medical – I(Grants/Research Funding); Galderma USA – A(H); L'Oreal USA Inc. – C(H); Novartis – A(H); Ortho Dermatologics – A(H); Sensus Healthcare – A(H); Suneva Medical, Inc. – A(H); Verrica Pharmaceuticals Inc – A(H);
  • Ferris, Laura K., MD, PhD: Abbott Laboratories – I(OB); Amgen – I(OB); Boehringer Ingelheim – I(OB); Castle Biosciences, Inc – C(H), I(OB); Celgene Corporation – I(OB); DermTech International – C(H), I(OB); Eli Lilly and Company – I(OB); Janssen Pharmaceuticals, Inc – C(H); Janssen Research & Development, LLC – I(OB); LEO Pharma, US – I(OB); Medimmune – I(OB); Novartis – A(H), I(OB); Pfizer Inc. – I(OB); Regeneron – I(OB);
  • Fromowitz, Jeffrey S., MD: Allergan, Inc – A(H); Aqua – SP(H); Cutera, Inc. – SP(H); DUSA Pharmaceuticals, Inc. – SP(H); Galderma Laboratories, L.P. – A(H), SP(H); Medicis Pharmaceutical Corporation – SP(H); Onset Dermatologics – SP(H); Pfizer Inc. – SP(H); TKL Research – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(H);
  • High, Whitney A., MD, JD: no financial relationships exist with commercial interests.
  • Leachman, Sancy A., MD, PhD: Castle Biosciences, Inc – I(NC); DermDetect – A(NC); Merck & Co., Inc – A(NC); Myriad Genetics Inc – I(NC); OrLucent, Inc. – A(H); Palvella Therapeutics – A(NC); Skin Cancer Free – B(NC); Veriskin – A(NC);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Almirall – C(H); Amgen – I(Grants/Research Funding); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Avotres, Inc. – C(H); BirchBioMed – C(H); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Cara Therapeutics – C(H); Castle Biosciences, Inc – C(H); Celgene Corporation – I(Grants/Research Funding); Clinuvel – I(Grants/Research Funding); Corrona, Inc. – O(H); Dermavant Sciences – C(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Inozyme Pharma – C(H); Janssen Research & Development, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); LEO Pharma, US – I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Meiji Seika Pharma Co., Ltd – C(H); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Neuroderm LTD – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – C(H); Vidac Pharma – I(Grants/Research Funding);
  • Lim, Henry W., MD: Beiersdorf, Inc. – I(Grants/Research Funding); Eli Lilly and Company – Speaker/Faculty Education(H); Estee Lauder – I(Grants/Research Funding); Ferndale Laboratories, Inc. – A(H), I(Grants/Research Funding); Galderma Laboratories, LP – A(H); Incyte Corporation – I(Grants/Research Funding); ISDIN – C(Fees); Pierre Fabre Dermatologie – C(Fees), Speaker/Faculty Education(H); Unigen – I(Grants/Research Funding);
  • Marghoob, Ashfaq A., MD: 3Gen, LLC – C(NC), O(EQ), O(NC), SP(H); American Dermoscopy Meeting – F(OB); Canfield Scientific, Inc. – C(NC), O(EQ), O(NC); Heine – C(NC), O(EQ); Informa HealthCare – O(OB); JP Medical Publishers – O(OB); Springer Publishing – O(OB); UpToDate, Inc – O(H);
  • Rigel, Darrell S., MD: Aclaris Therapeutics, Inc. – C(H); Beiersdorf, Inc. – A(H); Castle Biosciences – A(H), I(Grants/Research Funding); Derm Tech International – A(H), C(H); Ferndale Laboratories, Inc. – C(H); Foamix – SH(SO); LEO Pharma, US – A(H); Myriad Genetics Inc – A(H); Novartis – A(H); Ortho Dermatologics – A(H); Pierre Fabre Dermo-Cosmétique US – A(H); SciBASE – C(H);
  • Wang, Steven Q., MD: Avon Products, Inc. – A(H); L'Oreal USA Inc. – A(H); Neutrogena Corporation – C(H);
Monday, March 4
9:00 AM
Dr. Rigel / Introduction: Why the issue is Important
9:05 AM
Dr. Ceilley / Field vs Lesional Therapies for AKs – When to use Which?
9:18 AM
Dr. Farberg / Using Hedgehog Inhibitors in practice. Current and future Challenges
9:31 AM
Dr. Wang / Oral supplements in photoprotection
9:44 AM
Dr. Lim / Dilemmas associated with Oxybenzone in Sunscreens
9:57 AM
Dr. Fromowitz / Is superficial radiation no longer a forgotten approach for NMSC
10:10 AM
Dr. Lebwohl / Do Biologics cause skin cancer?
10:23 AM
Dr. Ceilley, Dr. Wang, Dr. Lim, Dr. Fromowitz, Dr. Lebwohl, and Dr. Farberg / Q&A
10:30 AM
Dr. Leachman / Assessing Melanoma Risk with Genetic Testing: Who and When?
10:43 AM
Dr. Rigel / The Dilemma of the Dysplastic Nevus – How are your colleagues managing these lesions?
10:56 AM
Dr. Marghoob / Key Factors in successful integration of Dermoscopy in your clinical setting
11:09 AM
Dr. High / New approaches in Pigmented lesion diagnosis – Pathology genetics and devices
11:22 AM
Dr. Ferris / Integrating Genetics into assessing skin cancer prognosis
11:35 AM
Dr. Desai / Skin Cancer Issues in Skin of Color
11:50 AM
Dr. Marghoob, Dr. Ferris, Dr. High, Dr. Desai, Dr. Rigel, and Dr. Leachman / Q&A
Event Details
  • Date
    Monday, March 4
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 209A
  • CME Credits
  • Type
  • Darrell S. Rigel, MD, FAAD
  • Ashfaq A. Marghoob, MD, FAAD - Handout
  • Henry W. Lim, MD, FAAD - Handout
  • Jeffrey S. Fromowitz, MD, FAAD
  • Laura K. Ferris, MD, PhD, FAAD
  • Mark Lebwohl, MD, FAAD - Handout
  • Roger I. Ceilley, MD, FAAD
  • Seemal R. Desai, MD, FAAD
  • Steven Q. Wang, MD, FAAD
  • Whitney A. High, MD, JD, FAAD